Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Puma Biotechnology, Inc. PBYI
$2.84
-$0.12 (-4.38%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
140588070.00000000
-
week52high
5.16
-
week52low
1.60
-
Revenue
228000000
-
P/E TTM
18039
-
Beta
1.01141800
-
EPS
0.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 05 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 06 мая 2022 г. |
| Citigroup | Buy | Neutral | 28 сент 2021 г. |
| RBC Capital | Sector Perform | Sector Perform | 06 авг 2021 г. |
| Goldman Sachs | Sell | Sell | 06 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 31 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wong Alvin F | D | 54553 | 3460 | 03 янв 2023 г. |
| NOUGUES MAXIMO F | D | 100427 | 10499 | 03 янв 2023 г. |
| Ludwig Jeffrey Jerome | D | 58057 | 6568 | 03 янв 2023 г. |
| AUERBACH ALAN H | D | 6852638 | 27241 | 03 янв 2023 г. |
| HUNT DOUGLAS M | D | 71350 | 4225 | 03 янв 2023 г. |
| AUERBACH ALAN H | A | 6879879 | 568181 | 12 дек 2022 г. |
| Wong Alvin F | D | 58013 | 514 | 02 дек 2022 г. |
| NOUGUES MAXIMO F | D | 110926 | 159 | 02 дек 2022 г. |
| HUNT DOUGLAS M | D | 75575 | 429 | 02 дек 2022 г. |
| AUERBACH ALAN H | D | 6311698 | 1251 | 02 дек 2022 г. |
Новостная лента
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y
Zacks Investment Research
05 мая 2023 г. в 14:27
Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.
Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 22:54
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chairman, President and CEO Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Ed White - H.C. Wainwright Divya Rao - TD Cowen Operator Good afternoon.
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates
Zacks Investment Research
04 мая 2023 г. в 19:44
Puma Biotech (PBYI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.08 per share a year ago.
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
Zacks Investment Research
03 мар 2023 г. в 15:48
Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.
Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript
Seeking Alpha
02 мар 2023 г. в 18:29
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director of IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Dave Rao - Cowen and Company Sahil Kazmi - B. Riley Securities Operator Good afternoon.